Benzinga’s Top Ratings Upgrades, Downgrades For November 29, 2022
Upgrades According to Wedbush, the prior rating for The GEO Group Inc (NYSE:GEO) was changed from Neutral to…
Medicenna Presents Preclinical Data At Cytokines 2022
-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer
--IL-4/IL-13
HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Medicenna Therapeutics (NASDAQ:MDNA) with a Buy and lowers the price target from $5 to $4.
Medicenna Therapeutics: Q1 Earnings Insights
Medicenna Therapeutics (NASDAQ:MDNA) reported its Q1 earnings results on Monday, August 15, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
MDNA: Unconfirmed Partial Response in Pancreatic Cancer Patient…
By David Bautz, PhD
NASDAQ:MDNA
READ THE FULL MDNA RESEARCH REPORT
Medicenna Therapeutics Q1 EPS $(0.07) Misses $(0.06) Estimate
Medicenna Therapeutics (NASDAQ:MDNA) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 30 percent increase over losses of $(0.10) per share
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell
• Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
A Preview Of Medicenna Therapeutics Earnings
Medicenna Therapeutics (NASDAQ:MDNA) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement.